John Quisel, Disc Medicine CEO
April 1, 2024 11:02 AM EDT
R&D

Disc Med­i­cine blames 'out­sized' place­bo re­sponse on mixed Phase 2 da­ta in rare blood dis­or­der

Amber Tong

De­spite dri­ving re­duc­tions in a key bio­mark­er, Disc Med­i­cine’s drug for a rare blood dis­or­der flunked on ef­fi­ca­cy in a Phase 2 study. The com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NIH’s fund­ing cut plan pos­es chal­lenges for re­searchers de­spite court halt

Ab­b­Vie pens an­oth­er T cell en­gager deal, this time with Xilio

Anap­tys­Bio gets a mid-stage win for PD-1 drug in rheuma­toid arthri­tis

Bio­gen down­plays ca­pac­i­ty for M&A; Roche’s SMA drug is ap­proved as a tablet

Novo's weight loss drug helps curb some drink­ing habits, small study shows

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times